We have a clinically de-risked product portfolio and pipeline:

AT278: Best-in-class, ultra-concentrated, ultra-rapid-acting insulin

  • Designed to transform AID systems, lowering burden and improving outcomes
  • Partnered with Sequel Med Tech, a leading US insulin pump device company
  • Addressing multi-billion $ diabetes market
  • Phase 2 ready by mid-2026

Next-generation drug delivery platform development for oral delivery of peptides

  • Addressing multi-billion $ obesity market
  • Initial target: Oral GLP-1 receptor agonist
  • Pre-clinical data to be generated during 2026

Strong corporate and financial position

  • Experienced leadership team and strong IP position
  • Cash balance of £6.1 million at the end of December 2025
  • Revenue generating from partnerships with leading pharma and biotech companies

We partner with leading pharmaceutical, biotech and medtech companies:

  • Co-development agreement with Sequel Med Tech to undertake preparatory work for Phase 2 clinical trial for combined AT278 /Insulin Pump programme
  • Continued revenue generation and significant future upside potential

Our validated technology

  • World-leading Arestat® drug formulation technology platform
  • Applicable to high-value biologics, including peptides, as well as future potential applications such as oral delivery, mRNA and cell & gene therapies
  • Third party validation and license revenue from diversified customer base across disease areas
  • Extensive IP protection with >100 granted patents in US, Europe and other key territories